Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Beijing Da Xue Xue Bao. Yi Xue Ban = Journal of Peking University. Health Sciences|December 22, 2017
[Impact of different surgical methods of radical cystectomy on the perioperative complications in patients over 75 years]Y S Meng, Y Wang, Y Fan, et al.
Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]|October 20, 2017
[The impact to operation safety of preoperative renal artery embolization for management of diameter≥10 cm renal cell carcinoma]Z Jia, X S Li, C J Zhang, et al.
Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]|December 12, 2017
[Clinical features and prognosis of rare subtypes of renal cell carcinoma]C M Ding, X S Li, C J Zhang, et al.
Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]|March 14, 2018
[Clinical features analysis of metanephric adenoma: a series of 16 cases]Z Jia, C J Zhang, C G Xi, et al.
Beijing Da Xue Xue Bao. Yi Xue Ban = Journal of Peking University. Health Sciences|August 18, 2017
[Percutaneous biopsy of the renal masses under ultrasound: a single-center 14 years experience]Y X Zhang, X B Meng, L Yao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 11, 2024
Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib/II dose-escalation and dose-expansion studyL Zhou, K W Yang, S Zhang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2023
Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III studyX Q Yan, M J Ye, Q Zou, et al.
Pageof 3